Kornimate/medical-research-clean huggingface dataset:
microbiota modification for the treatment of motor complication of parkinson´s disease

Conditions: Parkinson's Disease Aggravated

Summary: in recent years, abnormalities in gut microbiota have been identified in patients with parkinson´s disease having a possible role in motor manifestations. among 80 patients with pd, we selected 14 with lid and motor fluctuations with limited response to pharmacological therapy to receive treatment with sodium phosphate enema, oral rifaximin and polyethylene glycol to improve motor complications.

we studied consecutive patients diagnosed with pd according to the queen square brain bank criteria \[hughes et al 1992\] in a tertiary care center for movement disorders, from june 2018 to march 2020.

Eligibility criteria:
inclusion criteria: - patients aged 18-years old or older with moderate to severe dyskinesia and/or motor fluctuations with incomplete or poor response to adjustments in time and dose of levodopa and other anti-parkinsonian agents such as entacapone, rasagiline, dopamine receptor agonists and amantadine in 1-2 months prior to enrollment; defined by a movement disorders society unified parkinson´s disease rating scale (mds-updrs) part iv score equal or higher than 8 following pharmacological adjustments. exclusion criteria: * patients with chronic renal failure, decompensated heart failure, colonic abnormalities precluding the use of evacuating enema, known allergies to prescribed medications to reduce microbiota load and patients who declined to participate in the study.

Keywords: parkinson´s disease constipation dyskinesia microbiota
cardiovascular screening for family members of people with acute coronary disease

Conditions: Cardiovascular Risk Factor

Summary: over a 12-month period, patients admitted with acute coronary disease to the cardiovascular care unit at the jewish general hospital (jgh), an academic tertiary care referral center in montreal, quebec, will be approached to refer first-degree relatives and/or household members age 18 years or older to an outpatient cardiovascular (cv) risk factor screening and treatment program. relatives and household members will undergo a focused history, physical, and cv risk factor assessment and will receive evidence-based guideline-recommended treatment as indicated. participants will be referred to nutritionists, smoking cessation programs, and to other allied healthcare professionals as needed. a follow-up visit at 6-months will assess treatment adherence and improvement in cv risk factors. all family and/or household members including the index patient will be encouraged to attend all healthcare visits together. the effectiveness of the screening strategy will be measured by the total number of participants identified as intermediate or high modified framingham 10-year risk of cardiovascular disease. the effectiveness of the primary prevention intervention will be measured by the change in percentage of the mean modified framingham 10-year risk score for participants between the initial visit and 6-month follow-up. the value of the referral, screening, and treatment program, as well as participant engagement and satisfaction will also be systematically evaluated.


Eligibility criteria:
inclusion criteria: * patient age ≤70 years old admitted with an initial diagnosis of an acute coronary event (such as acute coronary syndrome or myocardial infarction) * at least 1 first-degree family or household member age ≥ 18 years old exclusion criteria * no eligible family or household members * inability to contact family or household members * distance to study centre too far as determined by the patient * family or household members who have been screened for cv disease in the previous 2 years. * family or household members with known coronary disease.
computerized registry of patients with venous thromboembolism (riete)

Conditions: Venous Thromboembolism

Summary: the computerized registry of patients with venous thromboembolism (riete) is a multidisciplinary project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. the main objective is to provide information on the internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events. as an additional objective riete is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications. the primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. study endpoints are clinically recognized (and objectively confirmed) recurrences of vte, major and minor bleeding complications, and death.

the riete registry pretends the improvement of care of patients with thromboembolic disease. very often the investigators pose serious doubts on how to manage a specific patient. sometimes because it is a patient with thrombocytopenia, a pregnant woman, a patient with a recent cerebral bleeding or cerebral metastasis, a patient with gastroduodenal ulcer or hepatic cirrhosis. there is no clinical evidence about how the investigators should manage these patients and the investigators have to individualize its management. the bibliography available is not of much help. only if the investigators have a database with a sufficient number of cases, they may be able to make evidence based decisions. this database on the internet will allow the investigators to consult and obtain an immediate response when taking care of a patient who needs an individualized management. after introducing the patient the investigators will automatically obtain the data of all patients with similar clinical profiles. and this will help the investigators to identify high-risk patients and thus facilitate them preventing possible future complications.

Eligibility criteria:
inclusion criteria: * confirmed vte (acute deep-vein thrombosis, pulmonary embolism and/or superficial venous thrombosis) by objective tests. * informed consent to the participation in the study, according to the requirements of the ethics committee within each hospital. exclusion criteria: * participation in a therapeutic clinical trial with an unknown drug. * inability to the 3 month follow-up
non-interventional study for real-world data of afatinib treatment in first-line setting and of subsequent therapies for patients with advanced epidermal growth factor receptor (egfr) mutation-positive lung adenocarcinoma

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Summary: the primary objective is to confirm time on treatment (tot) related to afatinib treatment as first-line therapy in patients with epidermal growth factor receptor (egfr) mutation-positive non-small cell lung cancer (nsclc). the observation in the real-world setting of the time from the start of the first-line afatinib until the end of subsequent treatment in this study will provide insights on the sequence of treatment for patients. the japanese healthcare system will enable this study to evaluate multiple treatment options after afatinib treatment.


Eligibility criteria:
inclusion criteria: * patients with epidermal growth factor receptor (egfr) mutation-positive advanced non-small cell lung cancer (nsclc) * patients who were/are treated with afatinib in the first-line setting at least 20 months\* prior to data entry * patients 20 years of age or older at the time of consent * patients who provided consent to participate in this study (for cases of death or lost to follow-up, instructions from the ethic committee (ec)/institutional review board (irb) at each site should be followed) \* inclusion will be restricted to patients with treatment initiation with afatinib at least 20 months prior to enrolment to avoid early censoring. exclusion criteria: * any contraindication to afatinib as specified in the label of giotrif® * patients treated with afatinib within an interventional trial * patients with active brain metastases at start of afatinib treatment\* \* patients with non-active brain metastases (asymptomatic state) are eligible.
art therapy in palliative care: study of identification and understanding of the mechanisms of change in the patient

Conditions: Psychological Stress; Suffering; Advanced Cancers

Summary: this study evaluates from the patient's perspective which elements of the own artistic creative process are the source of a beneficial change for him/her and how those elements influence in their end of life experience.

in previous quantitative studies about the effect of an art therapy intervention in adult cancer inpatients of the palliative care unit, the investigators evidenced significant improvements in the symptom control of malaise, anxiety, depression and pain. this study is designed to deepen the understanding of specific action mechanisms which lead to those therapeutic benefits and quality of life implications for patients with life-threatening illness in which a situation of suffering is frequently detected. the investigators will determine from the subjective patient's experience which specific elements of the artistic creative process (including production of art and art products) may lead to changes in the symptom perception, in meaning and healing process and in the personal perspective about the end of life situation.

Eligibility criteria:
inclusion criteria: * advanced-cancer adult inpatients of the palliative care unit * informed consent exclusion criteria: * altered cognitive function (mini-mental test \< 24) * physical decline (palliative care team's criteria) that impedes the art therapy process
brown adipose tissue metabolism in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: activation of brown adipose tissue (bat) by cold exposure. bat thermogenesis and bat volume of metabolic activity will be assessed by positron-emitting-tomography (pet/ct) and mri/mrs imaging and new pharmacological methods to modulate bat thermogenesis. all previous data on the functioning of brown adipose tissue (bat) were obtained by positron-emitting-tomography (pet) imaging studies using fluorodeoxyglucose f18 ( \[18f\]- fdg). this approach underestimates the actual activity of the bat. in this study, the investigator is going to use a new pet tracer (c11-palmitate) which is a fat molecule. this will allow to quantify more accurately the activity of brown fat.

the study protocol includes three visits: the screening visit (v1) and two pet/mri imaging studies (v2 and v3) performed in random order at an interval of 7 to 14 days. pet/ mri studies will be performed with and without nicotinic acid. a total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg, through v2 (protocol a): one dose at time 0, 60 minutes, 120 minutes and 180 minutes. during v2 and v3, participants will undergo acute cold exposure to stimulate brown adipose tissue. the morning of each pet imaging study, the participants will follow an mri acquisition to determine hepatic, pancreatic, visceral and bat lipid content, followed by an mrs acquisition in the hepatic and cervico-thoracic region. mri and mrs acquisition of the hepatic and cervico-thoracic region will be repeated again at the end of the day. the radioactive pet tracers used in this study are the \[11c\]-acetate, \[11c\]-palmitate and \[18f\]-fdg followed by dynamic and whole-body scans. stable isotopes such as \[u-13c\]-palmitate (0.08 umol/kg/min), 5d-glycérol (0.1 µmol/kg/min,) and tritiated glucose (of 1.5 uci/min) will be perfused from the start of the day until time 180 min.

Eligibility criteria:
inclusion criteria: * 10 men and 10 women with t2d. * 10 non-diabetic men and 10 non-diabetic women (matched for sex, bmi and age to the t2d participants). exclusion criteria: * change in weight of more than 2 kg over the past 3 months or recent changes in lifestyle; * treatment with a fibrate, thiazolidinedione, insulin, beta-blocker, glp-1 agonist, or other drug known to affect lipid or carbohydrate metabolism, except statins, metformin, sulfonylurea, dpp-iv inhibitor and other antihypertensive agents that can be temporarily stopped safely prior to the studies, as per our approved protocols; * presence of overt cardiovascular, liver, renal or other medical conditions; * smoking or consumption of more than 2 alcoholic beverages per day; * any other contraindication to temporarily suspending current medications for lipids or hypertension; * any contraindication to mri scanning. * having participated to a research study with exposure to radiation in the last two years before the start of the study.
a safety and efficacy study of de-120 injectable solution for age-related macular degeneration

Conditions: Age-Related Macular Degeneration

Summary: the purpose of the study is to evaluate the safety and efficacy of intravitreal (ivt) administration of de-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (cnv) secondary to age-related macular degeneration (amd).


Eligibility criteria:
inclusion criteria: * provide signed written informed consent * diagnosis of active cnv secondary to wet amd, with some subfoveal component in the study eye * no evidence of subfoveal fibrosis or subfoveal rpe atrophy in the study eye * at least one lesion in the study eye that meets minimal pathology criteria * best corrected visual acuity of 70 to 25 etdrs letters in the study eye * best corrected visual acuity of 20/320 or better in the fellow eye * reasonably clear media and some fixation in the study eye exclusion criteria: ocular * aphakic or has an anterior chamber intraocular lens in the study eye * received prior treatment with anti-vegf, intravitreal corticosteroids or photodynamic therapy in the study eye * uncontrolled glaucoma despite anti-glaucoma therapy in the study eye * evidence of any ocular disease other than amd in the study eye that may confound the outcome of the study * history of vitrectomy in the study eye * need for ocular surgery in the study eye during the course of the trial * presence or history of certain ocular or periocular pathology or conditions that could limit ability to perform required study assessments in either eye and/or confound study results non-ocular * allergy or hypersensitivity to study drug product, fluorescein dye or other study-related procedures and medications * current or history of certain systemic conditions, abnormalities or therapies that would render a subject a poor candidate for the study * participation in other investigational drug or device clinical trials within 30 days prior to randomization or planning to participate in other investigational drug or device clinical trials for the duration of the study * females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions and men who do not agree to practice an acceptable method of contraception throughout the course of the study * unable to comply with study procedures or follow-up visits

Keywords: macular degeneration
comparison of screw and suture button technique results in ankle syndesmosis injuries

Conditions: Ankle Injuries; Syndesmotic Injuries; Tibiofibular; Dislocation Distal

Summary: in this study, syndesmosis injuries were detected in 143 of the patients who came to atatürk university faculty of medicine, orthopedics and traumatology clinic from october 2017 to october 2021 with ankle fractures. 33 of these patients couldn't followed for various reasons. screw or suture buttone method was applied on 110 patients. and patients were examined with lots of data to compare their results. a retrospective study was conducted.


Eligibility criteria:
inclusion criteria: * ankle fractures associated with syndesmotic injury * age group 19-91 years * dislocation or non-dislocation ankle fractures * fractures due to acute injury (less than 3 weeks) * patient compliance with follow-up exclusion criteria: * patients younger than 18 years of age * conservative treatment * pathological and neglected fractures * patient's non-compliance with follow-up
study of maternal and fetal cardiovascular function in hypertensive states of pregnancy

Conditions: Preeclampsia

Summary: the pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. that is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). the goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * women with singleton and twin pregnancies complicated by hypertensive states of pregnancy. exclusion criteria: * minors under 18 years of age. * women with mental disabilities. * major congenital fetal anomaly.
the effect of kinesiotape application in chronic low back pain

Conditions: Chronic Low-back Pain (cLBP)

Summary: this study was conducted to determine the effects of kinesiotaping (kt) and sham kt applied with exercise program on clinical parameters such as pain, sleep, and quality of life in postmenopausal women with chronic low back pain. a randomized controlled experimental design, characteristic of quantitative research, was utilized. the subjects consisted of 60 postmenopausal women. the visual analog scale (vas), roland morris disability questionnaire (rmdq) and pittsburgh sleep quality index (psqi) were used as data collection tools.

with rising life expectancy, women are expected to spend a third of their lives in the postmenopausal stage. consequently, focusing research on postmenopausal women is considered crucial. this study was conducted to determine the effects of kinesiotaping (kt) and sham kt applied with exercise program on clinical parameters such as pain, sleep, and quality of life in postmenopausal women with chronic low back pain. a randomized controlled experimental design, characteristic of quantitative research, was utilized. the subjects consisted of 60 postmenopausal women. the visual analog scale (vas), roland morris disability questionnaire (rmdq) and pittsburgh sleep quality index (psqi) were used as data collection tools.

Eligibility criteria:
inclusion criteria: * postmenopausal patients with chronic nonspecific mechanical low back pain for at least three months * vas score of at least 3 exclusion criteria: * patients with a neurologic deficit, history of lumbar surgery, inflammatory low back pain, spinal stenosis, spondylolisthesis, a history of cardiopulmonary disease preventing exercise, severe osteoporosis, or a skin infection in the application area

Keywords: chronic low back pain kinesiotape sleep quality
long-term investigation of resveratrol in obesity

Conditions: Obesity; Inflammation; Insulin Sensitivity; Osteoporosis

Summary: the aim of this study is to investigate potential metabolic effects of resveratrol in men with metabolic syndrome(otherwise healthy). the investigators hypothesize that resveratrol has an anti-inflammatory effect, and will increase insulin sensitivity, change the fat- and sugar-metabolism, and down-regulate bone-turnover.

the study will be done in a collaboration between two phd students, who focus on effects in adipose- and muscle- tissue, and bone tissue respectively. the investigators will look at changes in * inflammation-markers * biochemical markers of fat- and sugar-metabolism * gene-expression in fat- and muscle-tissue * body composition (dxa (whole body) and mr spectroscopy) * biochemical markers of bone-metabolism * bone mineral density (dxa scans) * bone structure (qct) * gene-expression and cytokines in bone marrow some of the volunteers will have their insulin sensitivity measured.

Eligibility criteria:
inclusion criteria: * male * 30-60 years old * metabolic syndrome * written informed consent exclusion criteria: * diabetes, thyroid or parathyroid disease, hypogonadism * treatment-requiring osteoporosis * heart, liver or kidney disease * present or previous malignancy * mr contraindication * alcohol dependency * weight \> 130 kilograms

Keywords: obesity inflammation metabolic syndrome insulin sensitivity osteoporosis bone turnover ectopic fat accumulation resveratrol
sonographic examination cubital tunnel release

Conditions: Ulnar Nerve Compression, Cubital Tunnel

Summary: the investigators want to compare changes in cross-sectional area (csa) of the ulnar nerve at the elbow after open release or endoscopic release.

the investigators want to compare changes in csa of the ulnar nerve at the elbow hypothesizing that us examination is a useful tool to detect unsuccessful release and defining which technique shows the best outcome in the first year postoperatively. the measurement of cross-sectional area (csa) as a diagnostic tool to detect entrapments syndrome in upper limbs has already been described. us typically demonstrates an abrupt narrowing and displacement of the nerve within the tunnel, possibly in association with a thickened retinaculum or a space-occupying lesions. previous studies prospectively compared sonographic outcomes after decompression of the median nerve at the wrist.

Eligibility criteria:
inclusion criteria: * history of paresthesia or numbness in the ulnar nerve distribution; * weakness or wasting of the small muscles of the hand; * a positive elbow flexion provocation test; * slowed motor conduction velocity in the ulnar nerve below 50 m/sec. exclusion criteria: * patients with normal nerve conduction studies; * prior surgery for cubital tunnel syndrome; * prior traumatic lesions of the elbow; * coexistent neurological diseases; * bone anormalities (cubitus valgus, deformities from previous elbow fractures, osteoarthritis with medial osteophytes ands loose bodies, heterotopic ossifications); * subluxating ulnar nerve; * space-occupying soft-tissue lesions.

Keywords: ulnar nerve compression, cubital tunnel
salivary diagnostic testing for ivf

Conditions: Infertility

Summary: this study aims to determine the performance of a salivary hormone competitive immunoassay for monitoring patients during treatment for infertility.

the goal of this study is to determine the performance of a salivary hormone competitive immunoassay for monitoring patient estrogen and progesterone levels during treatment for infertility using controlled ovarian stimulation (coh) and in vitro fertilization (ivf). specifically, inter- and intra-assay precision, correlation with serum measurements (the gold-standard), and user satisfaction will be determined. ultimately, the potential applicability and reliability of salivary steroid monitoring in ivf cycles will be assessed.

Eligibility criteria:
inclusion criteria: * patients undergoing in vitro fertilization (ivf) at a participating infertility center

Keywords: infertility in vitro fertilization (ivf) venopuncture-free treatment needle-free treatment